Abstract: A process for the crosslinking of at least one polymer selected from polysaccharides and derivatives thereof, which is carried out in an aqueous solvent by the action of an effective and non-excessive amount of at least one crosslinking agent, characterized in that it is carried out on a mixture containing at least one low-molecular weight polymer and at least one high-molecular weight polymer. A process for the preparation of an injectable monophase hydrogel of at least one crosslinked polymer selected from polysaccharides and derivatives thereof. Crosslinked polymers and injectable monophase hydrogels respectively obtainable by each of said processes.

Abstract: An inhibitor of heat shock protein 90 (HSP90) can include a coumermycin A1 analog having a structure that inhibits HSP90 greater than coumermycin A1. That is, the coumermycin A1 analog is not coumermycin A1. The coumermycin A1 analog can have an antiproliferative biological activity, which can be superior to coumermycin A1. The activity can include the coumermycin A1 analog inhibiting a C-terminus of HSP90.

Abstract: Provided are a VEGF production promoter, a hair quality improver, and an external preparation for skin, each of which has a VEGF production promoting activity and can be used as a pharmaceutical agent, a cosmetic, a food, or a material therefor. The VEGF production promoter, the hair quality improver, and the external preparation for skin each comprises, as an active ingredient, a cycloartane-type glycoside represented by the following general formula (1) (where R represents a xylose residue or an arabinose residue, and the ring D moiety represents any one of the following moieties a to f (where R1 represents a hydrogen atom or a methyl group, R2 represents a hydrogen atom or an acetyl group, R3 represents a hydrogen atom or a hydroxyl, group, R4 represents a hydrogen atom or a hydroxyl group, and Ac represents an acetyl group)).

Abstract: An agent for eliminating a drug and an accelerator for eliminating a drug which comprise hyaluronic acid or a salt thereof.

Abstract: Disclosed is a method for mass-producing 4?-ethynyl d4T (4?-ethynyl-2?,3?-didehydro-3?-deoxythymidine) by a simpler process at low cost. Specifically disclosed is a method for producing 4?-ethynyl d4T, which is characterized by comprising a step for introducing a triple bond-containing group into a furfuryl alcohol derivative or a levoglucosenone, by reacting the furfuryl alcohol derivative or levoglucosenone with a certain compound, and a step for reacting a compound represented by the formula (III), which is obtained by the aforementioned step, with thymine.

Abstract: The present invention relates to compositions comprising chitosan, in the form of drugs or food supplements, suitable for comprehensive therapeutic treatment or comprehensive prevention of the metabolic syndrome. Also described is their preparation. More generally, the invention concerns the use of chitosan for comprehensive therapeutic treatment or comprehensive prevention of the metabolic syndrome.

Abstract: There is provided a method of glycosylating an aminocoumarin compound comprising conjugating a sugar to the 4?-OH position of the core of the aminocoumarin compound. Also provided is an aminocoumarin compound glycosylated at the 4?-OH position of the core of the aminocoumarin compound. Further aspects of this invention provide this compound for use in therapy, more particularly for use as an antibiotic, or in anticancer treatment.

Abstract: The present invention is directed to a composition for treating bacterial skin infections, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and an antibacterial active ingredient. It discloses a composition for treating fungal skin infections along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) an active pharmaceutical ingredient (API) composition in the form of silver sulphadiazine used in treating bacterial skin infections, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water.

Abstract: A method for preparing a precursor used to label hepatocyte receptors is revealed. The precursor contains a bifunctional structure including trisaccharide and DTPA ligand. During synthesis processes of the precursor, silica gel columns and Reverse phase-18 (RP-18) columns are used for purification. Thus both the purification times and cost of each purification are reduced. Moreover, use diethyl ether to facilitate precipitation of products and remove a part of coupling reagent. Removing the coupling reagent helps purification of products. Furthermore, N?,N?-bis(carboxymethyl)-L-lysine hydrate and benzyl chloroformate are coupled to form a trisaccharide skeleton so as to ensure the yield rate of trisaccharide structure.

Abstract: The present invention is directed to L-proline and citric acid co-crystals of (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, pharmaceutical compositions containing said co-crystals and their use in the treatment glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X.

Abstract: Disclosed is a method of preparing cationic starch. The method includes preparing a starch suspension containing a cationization agent; performing ultrahigh pressure treatment on the starch suspension; and obtaining cationic starch from the starch suspension subjected to ultrahigh pressure treatment.

Abstract: Described is a microfluidic process for manufacturing partially cross-linked alginate solution, wherein the alginate solution is a homogenous liquid which exhibits an elastic response (G?) which is equal to or greater than its viscous response (G?). In particular, the process may comprise microfluidic mixing of sodium alginate and calcium gluconate solutions to provide an injectable partially cross-linked alginate solution.

Abstract: The present invention provides a glucose decomposition-suppressed solid preparation for dialysis among powdery or granular preparations for dialysis containing acetate-free solid organic acids as pH adjusting agents. The present invention provides the solid preparation for dialysis containing electrolytes, glucose and pH adjusting agents characterized in that solid organic acids containing reduced amount of microparticles are used, and more specifically, characterized in that solid organic acids whose 20 or less percent of particles are 250 ?m or less in diameter, or solid organic acids whose 10 or less percent of particles are 150 ?m or less in diameter, are used. Preferably, the solid organic acid contained therein is citric acid.

Abstract: The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.

Abstract: The invention provides a bioadhesive composition comprising a polysaccharide and an energy converter, wherein the energy converter is activated by non-UV light. The composition may be prepared by dissolving the polysaccharide and the energy converter in an aqueous acidic solution. The composition, in the form of a film or a gel, may be used for repairing a discontinuity in an area of tissue or for joining tissue.

Abstract: A method and a mixture for treating and preventing the inflammatory bowel disease (IBD) by applying a predetermined therapeutically effective amount of a mixture of hyaluronic acid to individuals is disclosed. The mixture includes at least two different average molecular weight hyaluronic acids (Mw) with different rheology to gain a hyaluronic acid with the proper adhesion property, functions of tissue scaffold and insulation and treatment time, in order to treat and to prevent IBD (inflammatory bowel disease) includes ulcerative colitis, Crohn's disease or wound healing in stomach and intestine, thus to achieve the prompt treatment and to prolong the effect.

Abstract: The method of extracting kaempferol-based antioxidants from Solenostemma arghel provides a method of producing medicinal antioxidants for usage as anti-inflammatory and analgesic treatments. The kaempferol-based antioxidants are primarily kaempferol-3, 4?-diglucoside and kaempferol 3-rutinoside. The method includes the following steps: collecting aerial parts of Solenostemma arghel; drying the aerial parts; powdering the aerial parts; extracting the powdered aerial parts in ethanol and filtering to produce a filtrate; concentrating the filtrate to form a concentrated residue; dissolving the concentrated residue in water; and extracting the kaempferol-based antioxidant from the dissolved residue in ethyl acetate.

Abstract: A method for synthesizing an 18F-labeled probe. The method includes a step of eluting an amount of 18F with a first solvent which includes a predetermined amount of water and at least one organic solvent. In this step, the 18F elutes as an 18F solution. The method also includes a step of using the 18F solution to perform 18F-labeling in the presence of at least one labeling reagent and at least one phase transfer catalyst so as to generate the 18F-labeled probe. In the method, there is no step of drying the 18F starting from a time when the eluting step is performed and ending at a time when the 18F-labeling step is performed.

Abstract: The present invention relates to processes for preparing a glucopyranosyl-substituted benzyl-benzene derivative of general formula III, wherein R1 is defined according to claim 1.

Abstract: The present invention relates to an improved synthesis of a trisaccharide of the formula (1), novel intermediates used in the synthesis and the preparation of the intermediates.